---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-086135"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:09:30.995201+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Natera Q2 revenue up 40% to $198.2M; raises FY2022 guidance to $805M-$825M

## Summary
- Total revenue $198.2M (+39.6% YoY); product revenue $194.6M (+39.3%).
- Tests processed ~499,900, up 33% YoY; net loss $145.2M ($1.50/share) vs $116.0M ($1.32).
- 2022 revenue guidance raised to $805M-$825M; gross margin ~46%-48%.
- Cash & investments $638.7M, down from $914.5M at Dec 31, 2021; net cash consumption expected $370M-$400M.
- Selected for UnitedHealthcare Preferred Lab Network; Medicare coverage for Signatera in muscle invasive bladder cancer.

## SEC filing metadata
- accession: 0001104659-22-086135
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465922086135/0001104659-22-086135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465922086135/tm2222580d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-086135
- JSON: https://secwatch.observer/filing/0001104659-22-086135.json
- Plain text: https://secwatch.observer/filing/0001104659-22-086135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.